 This study is a multi-center, randomized, triple-blind, placebo-controlled parallel-group trial, in which each participant is offered an N-of-1 trial. The purpose of this study is to assess the efficacy and safety of melatonin 3 mg or 6 mg compared with placebo for initial insomnia in children with attention-deficit disorder. 